07:09:55 EDT Tue 29 Sep 2020
Enter Symbol
or Name

Login ID:
Trillium Therapeutics Inc (2)
Symbol TRIL
Shares Issued 21,238,831
Close 2019-04-01 C$ 0.95
Recent Sedar Documents

Trillium begins STING agonist program

2019-04-02 07:32 ET - News Release

Dr. Niclas Stiernholm reports


Trillium Therapeutics Inc. has expanded its immuno-oncology pipeline with a STING agonist program and presented preclinical data from this program at the 2019 annual meeting of the American Association for Cancer Research (AACR).

STING (stimulator of interferon genes) is an adaptor protein involved in sensing cytosolic DNA that plays a key role in promoting tumour immunity. STING has recently emerged as an attractive target in immuno-oncology, though the STING agonists currently in clinical trials are based on high molecular weight cyclic dinucleotide (CDN) scaffolds that possess certain undesirable drug properties. Trillium's AACR presentation described TTI-10001, a novel small molecule STING agonist that exhibits favourable potency, cell permeability and tumour retention properties that could potentially overcome the common limitations of current CDN-derived STING agonists. TTI-10001 is well tolerated in mice at relevant doses after intratumoural or intravenous delivery. Upon intratumoural administration, TTI-10001 monotherapy induced complete regressions in both injected and distal tumours and protected mice from subsequent tumour challenge, demonstrating the induction of durable immunity.

"Our STING agonist program builds upon the deep expertise we have developed in innate immunity through our work on CD47 and broadens our immuno-oncology pipeline," said Dr. Niclas Stiernholm, president and chief executive officer of Trillium Therapeutics. "STING is a promising target and we believe our compound has the potential to be a first-in-class small molecule agonist."

The poster will be available in the events and presentations section of Trillium's website.

About Trillium Therapeutics Inc.

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a do not eat signal that cancer cells frequently use to evade the immune system. Trillium also has a preclinical STING program and a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.